TOVX
HEALTHCARETheriva Biologics Inc.
AI Insight
What's Moving TOVX Today?
No stock-specific AI insight has been generated for TOVX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.16$0.86
$0.24
Fundamentals
Market Cap$12M
P/E Ratio—
EPS$-0.58
Dividend Yield—
Dividend / Share—
ROE-138.9%
Profit Margin—
Debt / Equity—
Trading
Volume693K
Avg Volume (10D)—
Shares Outstanding45.9M
TOVX News
19 articles- Theriva™ Biologics Announces Results from VCN-01 Phase 1 Clinical Trial in Head and Neck Cancer Published in Clinical Cancer ResearchYahoo Finance·Jun 11, 2026
- Theriva Biologics (NYSE: TOVX) fails quorum, delays 16.18M-warrant share voteStock Titan·Jun 5, 2026
- Theriva™ Biologics Reports First Quarter 2026 Operational Highlights and Financial ResultsYahoo Finance·May 5, 2026
- Theriva™ Biologics anuncia la próxima presentación de datos adicionales del ensayo clínico VIRAGE de Fase 2b del VCN-01 para el cáncer de páncreas metastásico en la Reunión Anual de la AACR de 2026GlobeNewswire Inc.·Apr 18, 2026
- Theriva™ Biologics Announces Upcoming Presentation of Additional Data from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer at AACR 2026 Annual MeetingYahoo Finance·Apr 17, 2026
- Theriva™ Biologics Announces Positive End-of-Phase 2 Meeting with U.S. FDA Regarding the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal AdenocarcinomaYahoo Finance·Mar 23, 2026
- Theriva™ Biologics Reports Full-Year 2025 Operational Highlights and Financial ResultsYahoo Finance·Mar 12, 2026
- Theriva™ Biologics Licenses SYN-020 to Rasayana Therapeutics for Multiple IndicationsYahoo Finance·Feb 18, 2026
- Theriva™ Biologics Announces Upcoming Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at APAO 2026Yahoo Finance·Feb 3, 2026
- Theriva Biologics receives CHMP scientific advice on VCN-01 Phase 3 designYahoo Finance·Dec 30, 2025
- Theriva™ Biologics Announces Positive Scientific Advice from the European Medicines Agency (EMA) on the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)Yahoo Finance·Dec 29, 2025
- Theriva Biologics: Q3 Earnings SnapshotYahoo Finance·Nov 12, 2025
- Theriva™ Biologics Reports Third Quarter 2025 Operational Highlights and Financial ResultsYahoo Finance·Nov 12, 2025
- Theriva Biologics Provides Response to Unusual Market ActionYahoo Finance·Oct 24, 2025
- Theriva™ Biologics Announces a Warrant Inducement Transaction for $4.0 Million in Gross ProceedsYahoo Finance·Oct 16, 2025
- Theriva™ Biologics Announces Upcoming Presentations at Medical MeetingsYahoo Finance·Oct 13, 2025
- Theriva™ Biologics Announces Presentation Describing Next Generation Oncolytic Adenovirus VCN-12 at the 32nd Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)Yahoo Finance·Oct 6, 2025
- Theriva Biologics: Q2 Earnings SnapshotYahoo Finance·Aug 11, 2025
- Theriva™ Biologics Reports Second Quarter 2025 Operational Highlights and Financial ResultsYahoo Finance·Aug 11, 2025
All 19 articles loaded
Price Data
Open$0.25
Previous Close$0.25
Day High$0.25
Day Low$0.24
52 Week High$0.86
52 Week Low$0.16
52-Week Range
$0.16$0.86
$0.24
Fundamentals
Market Cap$12M
P/E Ratio—
EPS$-0.58
Dividend Yield—
Dividend / Share—
ROE-138.9%
Profit Margin—
Debt / Equity—
Trading
Volume693K
Avg Volume (10D)—
Shares Outstanding45.9M
About Theriva Biologics Inc.
Theriva Biologics Inc., a clinical-stage company, develops therapies to treat diseases in areas of high unmet need. The company is headquartered in Rockville, Maryland.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNYSE MKT
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—